Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.

Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.

Item
http://www.wikidata.org/entity/Q33370619
Treatment of chronic immune thrombocytopenic purpura: the patients' perspective.Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysisThe potential utility of B cell-directed biologic therapy in autoimmune diseases.New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.Rituximab in the treatment of autoimmune haematological disorders.Repeated courses of rituximab in chronic ITP: Three different regimens.Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopeniaEfficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.Can rituximab replace splenectomy in immune thrombocytopenic purpura?Successful treatment of refractory idiopathic thrombocytopenic purpura and neutropenia with the monoclonal antibody, rituximabRituximab efficacy in the treatment of children with chronic immune thrombocytopenic purpura.A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience.Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two Phase 3, Randomized, Placebo-Controlled Trials.
P2860

Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.

Item
http://www.wikidata.org/entity/Q33370619
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Rituximab in the management of ...... native in refractory patients.
@ast
Rituximab in the management of ...... native in refractory patients.
@en
type
label
Rituximab in the management of ...... native in refractory patients.
@ast
Rituximab in the management of ...... native in refractory patients.
@en
prefLabel
Rituximab in the management of ...... native in refractory patients.
@ast
Rituximab in the management of ...... native in refractory patients.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Rituximab in the management of ...... rnative in refractory patients
@en
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921